PRECISION BIOSCIENCES INC
DTILPrecision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
28dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How DTIL's past catalysts played out
Fludarabine
Non-Hodgkin's Lymphoma, Relapsed
NPC-1C/NEO-102
Metastatic Pancreatic Cancer
NEO-201 in combination with pembrolizumab
Non Small Cell Lung Cancer
PBGENE-DMD (IV)
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine | Phase 2 | Non-Hodgkin's Lymphoma, Relapsed | - | - |
NPC-1C/NEO-102 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
NEO-201 in combination with pembrolizumab | Phase 2 | Non Small Cell Lung Cancer | - | - |
PBGENE-DMD (IV) | Phase 2 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PRECISION BIOSCIENCES INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in PRECISION BIOSCIENCES INC's (DTIL) pipeline across Phase 2. Its lead program is Fludarabine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PRECISION BIOSCIENCES INC's next FDA catalyst?→
PRECISION BIOSCIENCES INC's (DTIL) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DTIL biotech catalysts?→
Add DTIL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PRECISION BIOSCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.